Patents by Inventor J. Lester Matthews

J. Lester Matthews has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020198385
    Abstract: A class of predominantly hydrophilic 1,8-naphthalimide dyes. The dye contains at least two 1,8-naphthalimide ring systems, joined by a spacer moiety. Each of the 1,8-naphthalimide ring system has a ring nitrogen atom and bears, at the 4 position, an amino nitrogen atom, carrying a hydrogen. The remaining unsatisfied valences, if present, of the ring nitrogen atoms or the amino nitrogen atoms, or all, are occupied by one or more alkyl substituents. Each of the 1,8-naphthalimide ring system is free of an azo substituent and is also free of a nucleofuge. Upon activation by an activating agent in an environment independent of the presence or absence of oxygen, these compounds generate activated species. The activated species can cause structural changes in lipid and any associated proteins and polypeptides, extra- or intra-cellular or transmembrane, leading to polymerization and crosslinking.
    Type: Application
    Filed: June 21, 2002
    Publication date: December 26, 2002
    Applicant: MICROBIOMED CORP.
    Inventors: David E. Lewis, Ronald E. Utecht, Millard M. Judy, J. Lester Matthews
  • Patent number: 6410505
    Abstract: A class of predominantly hydrophilic 1,8-naphthalimide dyes. The dye contains at least two 1,8-naphthalimide ring systems, joined by a spacer moiety. Each of the 1,8-naphthalimide ring system has a ring nitrogen atom and bears, at the 4 position, an amino nitrogen atom, carrying a hydrogen. The remaining unsatisfied valences, if present, of the ring nitrogen atoms or the amino nitrogen atoms, or all, are occupied by one or more alkyl substituents. Each of the 1,8-naphthalimide ring system is free of an azo substituent and is also free of a nucleofuge. Upon activation by an activating agent in an environment independent of the presence or absence of oxygen, these compounds generate activated species. The activated species can cause structural changes in lipid and any associated proteins and polypeptides, extra- or intra-cellular or transmembrane, leading to polymerization and crosslinking.
    Type: Grant
    Filed: June 28, 1999
    Date of Patent: June 25, 2002
    Assignee: Microbiomed Corp.
    Inventors: David E. Lewis, Ronald E. Utecht, Millard M. Judy, J. Lester Matthews
  • Patent number: 5917045
    Abstract: A class of predominantly hydrophilic 1,8-naphthalimide dyes. The dye contains at least two 1,8-naphthalimide ring systems, joined by a spacer moiety. Each of the 1,8-naphthalimide ring system has a ring nitrogen atom and bears, at the 4 position, an amino nitrogen atom, carrying a hydrogen. The remaining unsatisfied valences, if present, of the ring nitrogen atoms or the amino nitrogen atoms, or all, are occupied by one or more alkyl substituents. Each of the 1,8-naphthalimide ring system is free of an azo substituent and is also free of a nucleofuge. Upon activation by an activating agent in an environment independent of the presence or absence of oxygen, these compounds generate activated species. The activated species can cause structural changes in lipid and any associated proteins and polypeptides, extra- or intra-cellular or transmembrane, leading to polymerization and crosslinking.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 29, 1999
    Assignee: MicroBioMed Corporation
    Inventors: David E. Lewis, Ronald E. Utecht, Millard M. Judy, J. Lester Matthews
  • Patent number: 5766600
    Abstract: A class of predominantly hydrophobic non-azo N-substituted 1,8-naphthalimide compounds, each bearing, at its 3-position, a nucleofuge and, at its 4-position, a heteroatomic electron-releasing group. The heteroatomic electron-releasing group is being characterized as having a heteroatom directly linked to the 4-position of the ring, and having at least one hydrogen directly attached to the heteroatom. Upon activation by an activating agent in an environment independent of the presence or absence of oxygen, these compounds generate activated species. The activated species initiate chemical changes in lipid bilayer membranes of viruses and other target cells. These changes can eradicate viruses and other target cells. The activated species can also cause structural changes in lipid and any associated proteins and polypeptides at a level beneath the surface of the membrane, leading to polymerization and crosslinking.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: June 16, 1998
    Assignee: MicroBioMed Corporation
    Inventors: David E. Lewis, Ronald E. Utecht, Millard M. Judy, J. Lester Matthews
  • Patent number: 5565551
    Abstract: A class of predominantly hydrophobic non-azo N-substituted 1,8-naphthalimide compounds, each bearing, at its 3-position, a nucleofuge and, at its 4-position, a heteroatomic electron-releasing group. The heteroatomic electron-releasing group is being characterized as having a heteroatom directly linked to the 4-position of the ring, and having at least one hydrogen directly attached to the heteroatom. Upon activation by an activating agent in an environment independent of the presence or absence of oxygen, these compounds generate activated species. The activated species initiate chemical changes in lipid bilayer membranes of viruses and other target cells. These changes can eradicate viruses and other target cells. The activated species can also cause structural changes in lipid and any associated proteins and polypeptides at a level beneath the surface of the membrane, leading to polymerization and crosslinking.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: October 15, 1996
    Assignee: MicroBioMed Corporation
    Inventors: David E. Lewis, Ronald E. Utecht, Millard M. Judy, J. Lester Matthews
  • Patent number: 5489590
    Abstract: A therapeutic composition derived from a pre-activated photoactive compound and a conveyor for destroying tumor or other pathogenic biological contaminants infecting animal body tissues. The conveyor can either be a matrix support or an antibody. The activation of the photoactive compound to produce the pre-activated photoactive compound is carried out by the use of an activating agent. The pre-activated photoactive compound retains its therapeutic activity subsequent to activation. A method for preparing such a therapeutic composition is disclosed. Methods for treating animal body tissue, either outside the body or inside the body, infected with tumors or other pathogenic biological contaminants are disclosed.
    Type: Grant
    Filed: February 3, 1992
    Date of Patent: February 6, 1996
    Assignee: Baylor Research Foundation
    Inventors: Kirpal S. Gulliya, Shazib Pervaiz, J. Lester Matthews, Robert M. Dowben, Jospeh T. Newman, Edward Forest
  • Patent number: 5472878
    Abstract: A method for the qualitative or quantitative determination of the deleterious agent in a substantially non-aqueous medium, such as an oil. The method involves using a non-azo 1,8-naphthalimide dye for the detection or quantitation of the total hydrogen ion activity in a substantially non-aqueous medium. The method includes the steps of: Mixing the dye with the substantially non-aqueous medium, which may or may not contain any hydrogen ion, to form a mixture; irradiating the mixture with a fluorescent light sufficient to cause the mixture to emit a detectable fluorescent emission spectrum; detecting the fluorescent emission spectrum of the mixture; and comparing the detected fluorescent emission spectrum with standard fluorescent emission spectra generated by reacting the dye with different known hydrogen ion activities, wherein differences between the fluorescent emission spectra compared are dependent upon the presence or levels of the hydrogen ion activity present in the mixture.
    Type: Grant
    Filed: June 8, 1994
    Date of Patent: December 5, 1995
    Assignee: MicroBioMed Corp.
    Inventors: David E. Lewis, Ronald E. Utecht, Millard M. Judy, J. Lester Matthews
  • Patent number: 5420136
    Abstract: A class of predominantly hydrophobic non-azo N-substituted 1,8-naphthalimide compounds, each bearing, at its 3-position, a nucleofuge and, at its 4-position, a heteroatomic electron-releasing group. The heteroatomic electron-releasing group is being characterized as having a heteroatom directly linked to the 4-position of the ring, and having at least one hydrogen directly attached to the heteroatom. Upon activation by an activating agent in an environment independent of the presence or absence of oxygen, these compounds generate activated species. The activated species initiate chemical changes in lipid bilayer membranes of viruses and other target cells. These changes can eradicate viruses and other target cells. The activated species can also cause structural changes in lipid and any associated proteins and polypeptides at a level beneath the surface of the membrane, leading to polymerization and crosslinking.
    Type: Grant
    Filed: August 9, 1993
    Date of Patent: May 30, 1995
    Assignee: MicroBioMed Corporation
    Inventors: David E. Lewis, Ronald E. Utecht, Millard M. Judy, J. Lester Matthews
  • Patent number: 5312919
    Abstract: This invention relates to novel photooxidation products, and derivatives thereof, of Merocyanine 540, their preparation and their uses as anticancer and antiviral agents.
    Type: Grant
    Filed: June 12, 1992
    Date of Patent: May 17, 1994
    Assignee: Baylor Research Institute
    Inventors: Kirpal S. Gulliya, Burchard Franck, J. Lester Matthews, Udo Schneider
  • Patent number: 5308773
    Abstract: The use of a class of non-azo 1,8-naphthalimide dyes for the detection and quantitation of a paramagnetic metal cation in a non-aqueous medium and some of the dyes that will complex with a paramagnetic metal cation. The concentration of the paramagnetic metal cation is determined by monitoring differences in the detected fluorescent emission spectra of the non-azo 1,8-naphthalimide dye solution when it is mixed with paramagnetic metal cations present in the non-aqueous medium. The detected fluorescent emission spectra will vary in relation to the presence or amount of the paramagnetic metal cation in the mixture.
    Type: Grant
    Filed: November 16, 1992
    Date of Patent: May 3, 1994
    Assignee: MicroBioMed Corp.
    Inventors: David E. Lewis, Ronald E. Utecht, Millard M. Judy, J. Lester Matthews
  • Patent number: 5235045
    Abstract: A class of predominantly hydrophobic non-azo N-substituted 1,8-naphthalimide compounds, each bearing, at its 3-position, a nucleofuge and, at its 4-position, a heteroatomic electron-releasing group. The heteroatomic electron-releasing group is being characterized as having a heteroatom directly linked to the 4-position of the ring, and having at least one hydrogen directly attached to the heteroatom. Upon activation by an activating agent in an environment independent of the presence or absence of oxygen, these compounds generate activated species. The activated species initiate chemical changes in lipid bilayer membranes of viruses and other target cells. These changes can eradicate viruses and other target cells. The activated species can also cause structural changes in lipid and any associated proteins and polypeptides at a level beneath the surface of the membrane, leading to polymerization and crosslinking.
    Type: Grant
    Filed: March 19, 1992
    Date of Patent: August 10, 1993
    Assignee: MicroBioMed Corporation
    Inventors: David E. Lewis, Ronald E. Utecht, Millard M. Judy, J. Lester Matthews
  • Patent number: 5177073
    Abstract: A therapeutic composition derived from a pre-activated photoactive compound and a conveyor for destroying tumor or other pathogenic biological contaminants infecting animal body tissues. The conveyor can either be a matrix support or an antibody. The activation of the photoactive compound to produce the pre-activated photoactive compound is carried out by the use of an activating agent. The pre-activated photoactive compound retains its therapeutic activity subsequent to activation. A method for preparing such a therapeutic composition is disclosed. Methods for treating animal body tissue, either outside the body or inside the body, infected with tumors or other pathogenic biological contaminants are disclosed.
    Type: Grant
    Filed: April 13, 1990
    Date of Patent: January 5, 1993
    Assignee: Baylor Research Institute
    Inventors: Kirpal S. Gulliya, Shazib Pervaiz, J. Lester Matthews, Robert M. Dowben, Joseph T. Newman, Edward Forest
  • Patent number: 5092864
    Abstract: A method and apparatus for providing greater precision placement and control of the delivery of laser energy during laser surgery is disclosed and includes a pulse-controlled dye delivery system which may be coordinated with the delivery of laser energy to predetermined tissue. The pulse-controlled dye delivery system comprises at least one ejection head capable of ejecting drops of liquid dye with the diameter of each drop being less than two hundred microns. The dye is responsive to the wavelength of energy delivered by the laser performing the surgery to convert the laser energy from the surgical laser to tissue thermal energy. Circuitry is provided for precisely activating the dye delivery system and the laser energy source such that optimal conditions for successful outcome of the surgery may be achieved.
    Type: Grant
    Filed: April 30, 1990
    Date of Patent: March 3, 1992
    Assignee: Microfab Technologies, Inc.
    Inventors: Donald J. Hayes, J. Lester Matthews, Millard M. Judy
  • Patent number: 5091385
    Abstract: A pre-activated therapeutic agent derived from a photoactive compound for destroying tumor or other pathogenic biological contaminants infecting animal body tissues. The activation of the photoactive compound is carried out prior to the photoactive compound is being brought into contact with the tissue to be treated. The resultant pre-activated therapeutic agent, or mixture, retains its therapeutic activity subsequent to activation. A method for preparing such a pre-activated therapeutic agent is disclosed. Methods for treating animal body tissue, either outside the body or inside the body, infected with tumors or other pathogenic biological contaminants are disclosed.
    Type: Grant
    Filed: September 30, 1988
    Date of Patent: February 25, 1992
    Assignee: Baylor Research Institute
    Inventors: Kirpal S. Gulliya, Shazib Pervaiz, J. Lester Matthews, Robert M. Dowben, Joseph T. Newman, Edward Forest
  • Patent number: 5041078
    Abstract: The present invention demonstrates a method of photodynamic inactivation of viruses having a membranous envelope, such as Herpes simplex type 1 and Human immunodeficiency type 1 viruses. The method uses substituted sapphyrin compounds to effect viral deactivation during radiation with light at or near the absorption wavelength of the sapphyrin compound. A highly reactive species selectively toxic to infectious agents is produced.One particular sapphyrin compound useful for the practice of the invention is 8,17-bis(carboxymethyl)-3,12,13,22-tetraethyl-2,7,18,23-tetramethylsapphyr in (Sapphyrin 2). The most preferred sapphyrin sapphyrin compound for the practice of the invention is 3,8,12,13,17,22-hexaethyl-2,7,18,23-tetramethylsapphyrin (Sapphyrin 1).The method is particularly suitable for inactivation of viruses in blood and blood products.
    Type: Grant
    Filed: December 21, 1989
    Date of Patent: August 20, 1991
    Assignees: Baylor Research Foundation, a nonprofit corporation of the State of Texas, Board of Regents, The University of Texas System
    Inventors: J. Lester Matthews, Millard M. Judy, Joseph T. Newman, Frank Sogandares-Bernal, Jonathan L. Sessler, Anthony Harriman, Bhaskar G. Maiya
  • Patent number: 4492577
    Abstract: A device is disclosed which has a solid interior and at least one surface which is porous. The porous surface has several desired characteristics, including: (1) the majority of pores have dimensions within a size range that encourages the migration of cells into said pores, such as about 50 to about 500 micron diameters, and (2) the pores have a controlled depth, such as about 300 microns or less. Such devices may be created by several methods, such as injecting casting material into a mold which is fitted with a shell of porous material having the desired shape and characteristics. Such devices are useful as artificial teeth and orthopedic appliances.
    Type: Grant
    Filed: October 25, 1982
    Date of Patent: January 8, 1985
    Inventors: Edward T. Farris, J. Lester Matthews